Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.

about

Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infection.

Item

http://www.wikidata.org/entity/Q40684633

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety and efficacy of faldapr ...... c hepatitis C virus infection.

@en

type

Item

label

Safety and efficacy of faldapr ...... c hepatitis C virus infection.

@en

prefLabel

Safety and efficacy of faldapr ...... c hepatitis C virus infection.

@en

P1476

Safety and efficacy of faldapr ...... c hepatitis C virus infection.

@en

P2093

Anne-Marie Quinson

http://www.w3.org/2001/XMLSchema#string

Atsushi Taniguchi

http://www.w3.org/2001/XMLSchema#string

Jerry O Stern

http://www.w3.org/2001/XMLSchema#string

Joseph Scherer

http://www.w3.org/2001/XMLSchema#string

Keiko Suzaki

http://www.w3.org/2001/XMLSchema#string

Kristi L Berger

http://www.w3.org/2001/XMLSchema#string

Masao Omata

http://www.w3.org/2001/XMLSchema#string

Shuhei Nishiguchi

http://www.w3.org/2001/XMLSchema#string

Yasuhisa Urano

http://www.w3.org/2001/XMLSchema#string

P2860

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.

Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease

Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.

Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

P304

E142-E151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HEPR.12741

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anne-Marie Quinson

P577

2016-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27153246

http://www.w3.org/2001/XMLSchema#string